Horn L-C, Einenkel J, Höckel M, Kölbl H, Kommoss F, Lax S F, Riethdorf L, Schnürch H-G, Schmidt D
Abteilung für Gynäko- & Perinatalpathologie, Institut für Pathologie der Universität Leipzig.
Pathologe. 2005 Jul;26(4):266-72. doi: 10.1007/s00292-005-0764-3.
The nodal status is one of the strongest prognostic factors in gynecologic malignancies. Metastatic involvement of regional and distant lymph nodes represents the selection basis for adjuvant therapy in a large number of solid neoplasms. The number of resected lymph nodes is one of the most important parameters in the quality control of the surgical procedure, in particular with respect to radicality. The present paper provides recommendations for gross dissection, laboratory procedures and reporting for lymph node biopsies, lymph node dissections and sentinel lymph node biopsies (SLN) for cancers of the vulva, vagina, uterine cervix, endometrium, Fallopian tubes and the ovaries, submitted for the evaluation of metastatic disease. The pathologic oncology report should include information about the number and size of resected lymph nodes, the number of involved lymph nodes with the maximum size of metastases and the presence of paranodal infiltration. In addition, the detection of isolated tumor cells should be reported, particularly with respect to the detection method (immunostains or molecular methods). In cases of metastatic disease and carcinoma of unknown primary (CUP-syndrome), information should be given regarding the primary tumor.
淋巴结状态是妇科恶性肿瘤最强的预后因素之一。区域和远处淋巴结的转移累及是大量实体肿瘤辅助治疗的选择依据。切除淋巴结的数量是手术质量控制中最重要的参数之一，尤其是在根治性方面。本文针对提交评估转移性疾病的外阴、阴道、子宫颈、子宫内膜、输卵管和卵巢癌的淋巴结活检、淋巴结清扫和前哨淋巴结活检（SLN），提供大体解剖、实验室操作和报告方面的建议。病理肿瘤学报告应包括切除淋巴结的数量和大小、受累淋巴结的数量及转移灶的最大尺寸，以及有无淋巴结旁浸润。此外，应报告孤立肿瘤细胞的检测情况，特别是检测方法（免疫染色或分子方法）。在转移性疾病和原发灶不明癌（CUP综合征）的病例中，应提供有关原发肿瘤的信息。
